` BCAB (Bioatla Inc) vs S&P 500 Comparison - Alpha Spread

B
BCAB
vs
S&P 500

Over the past 12 months, BCAB has underperformed S&P 500, delivering a return of -32% compared to the S&P 500's +16% growth.

Stocks Performance
BCAB vs S&P 500

Loading
BCAB
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BCAB vs S&P 500

Loading
BCAB
S&P 500
Difference
www.alphaspread.com

Performance By Year
BCAB vs S&P 500

Loading
BCAB
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Bioatla Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Bioatla Inc
Glance View

Market Cap
18.5m USD
Industry
Biotechnology

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidate includes BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin) and BA3071 (Ozuriftabmab vedotin). The Company’s lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL that is protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company has initiated a Phase I/II dose-escalation trial of BA3071 as monotherapy and in combination with an anti-PD-1 antibody with expansion cohorts to be enrolled upon identification of the recommended dose.

BCAB Intrinsic Value
0.3911 USD
Undervaluation 20%
Intrinsic Value
Price
B
Back to Top